RT Journal Article
SR Electronic
T1 Systemic adjuvant therapy for node-negative breast cancer
JF Canadian Medical Association Journal
JO CMAJ
FD Canadian Medical Association
SP 381
OP 387
VO 141
IS 5
A1 A. D. Ginsburg
A1 D. J. Perrault
A1 K. I. Pritchard
A1 G. P. Browman
A1 P. B. McCulloch
A1 J. Skillings
YR 1989
UL http://www.cmaj.ca/content/141/5/381.abstract
AB In response to recent advice from the US National Cancer Institute concerning the use of systemic adjuvant therapy for node-negative breast cancer we reviewed the literature and found that several studies have shown evidence of a disease-free, but not an overall, survival advantage for treated patients. The benefits have been modest and may not outweight the cost and toxic effects of such therapy. Routine use does not seem to be justified. Factors must be identified to differentiate between patients at low risk and those at high risk. It should then be determined if adjuvant therapy is truly beneficial in those who are at high risk.